Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsCharles J. Sherr, Dawn Quelle, Martine F. Roussel, Frederique Zindy
Estimating the term…
The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.
A method at inducing cell cycle arrest in a eukaryotic cell comprising administering to said cell an ARF-p19 polypeptide, wherein said ARF-p19 polypeptide
A method of inducing cell cycle arrest in a eukaryotic cell comprising administering to said cell an expression vector construct comprising a nucleic acid sequence encoding an ARF-p19 polypeptide, wherein said ARF-p19 polypeptide
A method of preventing abnormal cell growth in a cell, wherein said method comprises administering an effective amount of am ARF-p19 polypeptide or an active fragment of an ARF-p19 polypeptide, wherein said ARF-p19 polypeptide
A method of preventing abnormal cell growth in a cell, wherein said method comprises administering to said cell an expression vector construct comprising a nucleic acid sequence encoding an ARF-p19 polypeptide or an active fragment of ARF-p19 polypeptide, wherein said ARF-p19 polypeptide
Dependencies are inferred from the claim text.